Knight Therapeutics Inc
F:04K
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Knight Therapeutics Inc
F:04K
|
CA |
|
Tiziana Life Sciences Ltd
F:0RP
|
UK |
|
Atresmedia Corporacion de Medios de Comunicacion SA
F:YT2
|
ES |
|
E
|
Eskay Mining Corp
F:KN7
|
CA |
|
High Co SA
F:HIH
|
FR |
|
A
|
Acadian Timber Corp
F:779
|
CA |
|
Valion Bio Inc
NASDAQ:VBIO
|
US |
|
T
|
Texwinca Holdings Ltd
XMUN:TXW
|
HK |
|
N
|
Neotech Metals Corp
F:V690
|
CA |
Wall St Price Targets
04K Price Targets Summary
Knight Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 04K is 3.63 EUR with a low forecast of 3.29 EUR and a high forecast of 4.56 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 04K's stock price target?
Price Target
3.63
EUR
According to Wall Street analysts, the average 1-year price target for 04K is 3.63 EUR with a low forecast of 3.29 EUR and a high forecast of 4.56 EUR.
What is the Revenue forecast for Knight Therapeutics Inc?
Projected CAGR
7%
Over the last 10 years, the compound annual growth rate for Revenue has been 84%. The projected CAGR for the next 5 years is 7%.
What is the Gross Profit forecast for Knight Therapeutics Inc?
Projected CAGR
8%
Over the last 10 years, the compound annual growth rate for Gross Profit has been 79%. The projected CAGR for the next 5 years is 8%.
What is the Operating Income forecast for Knight Therapeutics Inc?
Projected CAGR
59%
The compound annual growth rate for Operating Income over the next 5 years is 59%.
